Zhitong Finance App News, Yiming Onko-B (01541.HK) announced that the Group has obtained approval from the US Food and Drug Administration for IMM0306's experimental new drug (IND) application for phase IB/II clinical trials to treat systemic lupus erythematosus (SLE).

Zhitongcaijing · 3d ago
Zhitong Finance App News, Yiming Onko-B (01541.HK) announced that the Group has obtained approval from the US Food and Drug Administration for IMM0306's experimental new drug (IND) application for phase IB/II clinical trials to treat systemic lupus erythematosus (SLE).